O	0	12	Introduction	Introduction	NN	B-NP

O	13	16	Tea	Tea	NNP	B-NP
O	17	18	(	(	(	O
O	18	26	Camellia	Camellia	NNP	B-NP
O	27	35	sinensis	sinensis	NNP	I-NP
O	36	37	L	L	NNP	I-NP
O	37	38	.	.	.	O
O	38	39	)	)	)	O
O	40	42	is	be	VBZ	B-VP
O	43	46	one	one	CD	B-NP
O	47	49	of	of	IN	B-PP
O	50	53	the	the	DT	B-NP
O	54	58	most	most	RBS	I-NP
O	59	65	widely	widely	RB	I-NP
O	66	74	consumed	consume	VBN	I-NP
O	75	84	beverages	beverage	NNS	I-NP
O	85	87	in	in	IN	B-PP
O	88	91	the	the	DT	B-NP
O	92	97	world	world	NN	I-NP
O	97	98	.	.	.	O

O	99	100	(	(	(	O
O	100	101	-	-	SYM	B-NP
O	101	102	)	)	)	O
O	102	103	-	-	HYPH	B-NP
O	103	119	Epigallocatechin	Epigallocatechin	NN	I-NP
O	119	120	-	-	HYPH	B-NP
O	120	121	3	3	CD	I-NP
O	121	122	-	-	HYPH	I-NP
O	122	123	O	O	NN	I-NP
O	123	124	-	-	HYPH	O
O	124	131	gallate	gallate	NN	B-NP
O	132	133	(	(	(	O
O	133	137	EGCG	EGCG	NN	B-NP
O	137	138	)	)	)	O
O	138	139	,	,	,	O
O	140	145	which	which	WDT	B-NP
O	146	148	is	be	VBZ	B-VP
O	149	152	the	the	DT	B-NP
O	153	158	major	major	JJ	I-NP
O	159	164	green	green	JJ	I-NP
O	165	168	tea	tea	NN	I-NP
O	169	177	catechin	catechin	NN	I-NP
O	178	185	present	present	JJ	B-ADJP
O	186	188	in	in	IN	B-PP
O	189	192	the	the	DT	B-NP
B-Organ	193	199	leaves	leaf	NNS	I-NP
O	199	200	,	,	,	O
O	201	203	is	be	VBZ	B-VP
O	204	212	believed	believe	VBN	I-VP
O	213	215	to	to	TO	B-PP
O	216	219	the	the	DT	B-NP
O	220	228	compound	compound	NN	I-NP
O	229	233	most	most	RBS	B-ADJP
O	234	245	responsible	responsible	JJ	I-ADJP
O	246	249	for	for	IN	B-PP
O	250	253	the	the	DT	B-NP
O	254	260	health	health	NN	I-NP
O	261	269	benefits	benefit	NNS	I-NP
O	270	280	attributed	attribute	VBN	B-VP
O	281	283	to	to	TO	B-PP
O	284	287	tea	tea	NN	B-NP
O	287	288	.	.	.	O

O	289	293	EGCG	EGCG	NN	B-NP
O	294	297	was	be	VBD	B-VP
O	298	306	reported	report	VBN	I-VP
O	307	309	to	to	TO	I-VP
O	310	314	have	have	VB	I-VP
O	315	328	antioxidative	antioxidative	JJ	B-NP
O	329	330	[	[	(	I-NP
O	330	331	1	1	CD	I-NP
O	331	332	]	]	)	O
O	332	333	,	,	,	O
O	334	335	[	[	(	O
O	335	336	2	2	CD	B-NP
O	336	337	]	]	)	O
O	337	338	,	,	,	O
O	339	352	antimutagenic	antimutagenic	JJ	B-NP
O	353	354	[	[	(	I-NP
O	354	355	3	3	CD	I-NP
O	355	356	]	]	)	O
O	356	357	,	,	,	O
O	358	362	anti	anti	AFX	B-NP
O	362	363	-	-	HYPH	I-NP
O	363	375	inflammatory	inflammatory	JJ	I-NP
O	376	377	[	[	(	I-NP
O	377	378	4	4	CD	I-NP
O	378	379	]	]	)	O
O	379	380	,	,	,	O
O	381	384	and	and	CC	O
O	385	401	anticarcinogenic	anticarcinogenic	JJ	B-NP
O	402	412	activities	activity	NNS	I-NP
O	413	414	[	[	(	O
O	414	415	5	5	CD	B-NP
O	415	416	]	]	)	O
O	416	417	.	.	.	O

O	418	426	Although	Although	IN	B-SBAR
O	427	430	the	the	DT	B-NP
O	431	435	EGCG	EGCG	NN	I-NP
O	436	450	concentrations	concentration	NNS	I-NP
O	451	459	required	require	VBN	B-VP
O	460	462	to	to	TO	B-VP
O	463	469	elicit	elicit	VB	I-VP
O	470	473	the	the	DT	B-NP
B-Cancer	474	484	anticancer	anticancer	JJ	I-NP
O	485	493	activity	activity	NN	I-NP
O	494	498	have	have	VBP	B-VP
O	499	503	been	be	VBN	I-VP
O	504	509	shown	show	VBN	I-VP
O	510	512	to	to	TO	I-VP
O	513	515	be	be	VB	I-VP
O	516	520	more	more	JJR	B-NP
O	521	525	than	than	IN	I-NP
O	526	527	1	1	CD	I-NP
O	528	534	microM	microM	NN	I-NP
O	534	535	,	,	,	O
O	536	539	the	the	DT	B-NP
B-Organism_substance	540	545	blood	blood	NN	I-NP
O	546	551	level	level	NN	I-NP
O	552	554	of	of	IN	B-PP
O	555	559	EGCG	EGCG	NN	B-NP
O	560	565	after	after	IN	B-PP
O	566	575	consuming	consume	VBG	B-VP
O	576	579	the	the	DT	B-NP
O	580	590	equivalent	equivalent	NN	I-NP
O	591	593	of	of	IN	B-PP
O	594	595	2	2	CD	B-NP
O	595	596	-	-	HYPH	I-NP
O	596	597	3	3	CD	I-NP
O	598	602	cups	cup	NNS	I-NP
O	603	605	of	of	IN	B-PP
O	606	611	green	green	JJ	B-NP
O	612	615	tea	tea	NN	I-NP
O	616	619	was	be	VBD	B-VP
O	620	621	0	0	CD	B-NP
O	621	622	.	.	SYM	I-NP
O	622	623	1	1	CD	I-NP
O	623	624	-	-	HYPH	I-NP
O	624	625	0	0	CD	I-NP
O	625	626	.	.	.	O
O	626	627	6	6	CD	B-NP
O	628	634	microM	microM	NN	I-NP
O	635	638	and	and	CC	B-PP
O	639	642	for	for	IN	B-PP
O	643	645	an	an	DT	B-NP
O	646	656	equivalent	equivalent	NN	I-NP
O	657	659	of	of	IN	B-PP
O	660	661	7	7	CD	B-NP
O	661	662	-	-	HYPH	I-NP
O	662	663	9	9	CD	I-NP
O	664	668	cups	cup	NNS	I-NP
O	669	672	was	be	VBD	B-VP
O	673	678	still	still	RB	B-ADJP
O	679	684	lower	low	JJR	B-NP
O	685	689	than	than	IN	I-NP
O	690	691	1	1	CD	I-NP
O	692	698	microM	microM	NN	I-NP
O	699	700	[	[	(	O
O	700	701	6	6	CD	B-NP
O	701	702	]	]	)	O
O	702	703	,	,	,	O
O	704	705	[	[	(	O
O	705	706	7	7	CD	B-NP
O	706	707	]	]	)	O
O	707	708	.	.	.	O

O	709	711	In	In	IN	B-PP
O	712	713	a	a	DT	B-NP
O	714	720	cohort	cohort	JJ	I-NP
O	721	726	study	study	NN	I-NP
O	726	727	,	,	,	O
O	728	733	daily	daily	JJ	B-NP
O	734	745	consumption	consumption	NN	I-NP
O	746	748	of	of	IN	B-PP
O	749	752	ten	ten	CD	B-NP
O	753	757	cups	cup	NNS	I-NP
O	758	760	of	of	IN	B-PP
O	761	766	green	green	JJ	B-NP
O	767	770	tea	tea	NN	I-NP
O	771	774	was	be	VBD	B-VP
O	775	783	required	require	VBN	I-VP
O	784	787	for	for	IN	B-PP
O	788	791	the	the	DT	B-NP
B-Cancer	792	798	cancer	cancer	NN	I-NP
O	799	809	preventive	preventive	JJ	I-NP
O	810	816	effect	effect	NN	I-NP
O	817	818	[	[	(	O
O	818	819	8	8	CD	B-NP
O	819	820	]	]	)	O
O	820	821	.	.	.	O

O	822	830	Moreover	Moreover	RB	B-ADVP
O	830	831	,	,	,	O
O	832	839	adverse	adverse	JJ	B-NP
O	840	847	effects	effect	NNS	I-NP
O	848	850	of	of	IN	B-PP
O	851	856	green	green	JJ	B-NP
O	857	860	tea	tea	NN	I-NP
O	860	861	,	,	,	O
O	862	868	mainly	mainly	RB	B-NP
O	869	878	hepatitis	hepatitis	NN	I-NP
O	878	879	,	,	,	O
O	880	882	by	by	IN	B-PP
O	883	894	consumption	consumption	NN	B-NP
O	895	897	of	of	IN	B-PP
O	898	902	high	high	JJ	B-NP
O	903	908	doses	dose	NNS	I-NP
O	909	911	of	of	IN	B-PP
O	912	917	green	green	JJ	B-NP
O	918	921	tea	tea	NN	I-NP
O	922	926	have	have	VBP	B-VP
O	927	931	been	be	VBN	I-VP
O	932	940	reported	report	VBN	I-VP
O	941	942	[	[	(	O
O	942	943	9	9	CD	B-NP
O	943	944	]	]	)	O
O	944	945	.	.	.	O

O	946	955	Therefore	Therefore	RB	B-ADVP
O	955	956	,	,	,	O
O	957	959	it	it	PRP	B-NP
O	960	962	is	be	VBZ	B-VP
O	963	972	important	important	JJ	B-ADJP
O	973	975	to	to	TO	B-VP
O	976	983	enhance	enhance	VB	I-VP
O	984	987	the	the	DT	B-NP
O	988	1001	pharmacologic	pharmacologic	JJ	I-NP
O	1002	1008	effect	effect	NN	I-NP
O	1009	1011	of	of	IN	B-PP
O	1012	1016	EGCG	EGCG	NN	B-NP
O	1017	1019	to	to	TO	B-VP
O	1020	1026	obtain	obtain	VB	I-VP
O	1027	1030	the	the	DT	B-NP
O	1031	1037	health	health	NN	I-NP
O	1038	1045	benefit	benefit	NN	I-NP
O	1046	1048	in	in	IN	B-PP
O	1049	1059	reasonable	reasonable	JJ	B-NP
O	1060	1073	concentration	concentration	NN	I-NP
O	1074	1076	in	in	IN	B-PP
O	1077	1082	daily	daily	JJ	B-NP
O	1083	1087	life	life	NN	I-NP
O	1087	1088	.	.	.	O

O	1089	1091	We	We	PRP	B-NP
O	1092	1096	have	have	VBP	B-VP
O	1097	1105	reported	report	VBN	I-VP
O	1106	1110	that	that	IN	B-SBAR
O	1111	1114	the	the	DT	B-NP
B-Cellular_component	1115	1119	cell	cell	NN	I-NP
I-Cellular_component	1119	1120	-	-	HYPH	B-NP
I-Cellular_component	1120	1127	surface	surface	NN	I-NP
O	1128	1135	binding	binding	NN	I-NP
O	1136	1138	of	of	IN	B-PP
O	1139	1143	EGCG	EGCG	NN	B-NP
O	1144	1147	and	and	CC	O
O	1148	1151	its	its	PRP$	B-NP
O	1152	1163	derivatives	derivative	NNS	I-NP
O	1164	1166	is	be	VBZ	B-VP
O	1167	1175	involved	involve	VBN	I-VP
O	1176	1178	in	in	IN	B-PP
O	1179	1184	their	their	PRP$	B-NP
O	1185	1195	biological	biological	JJ	I-NP
O	1196	1206	activities	activity	NNS	I-NP
O	1207	1208	[	[	(	O
O	1208	1210	10	10	CD	B-NP
O	1210	1211	]	]	)	O
O	1211	1212	-	-	HYPH	O
O	1212	1213	[	[	(	O
O	1213	1215	15	15	CD	B-NP
O	1215	1216	]	]	)	O
O	1216	1217	.	.	.	O

O	1218	1220	We	We	PRP	B-NP
O	1221	1225	have	have	VBP	B-VP
O	1226	1236	identified	identify	VBN	I-VP
O	1237	1240	the	the	DT	B-NP
O	1241	1243	67	67	CD	I-NP
O	1243	1244	-	-	HYPH	I-NP
O	1244	1247	kDa	kDa	NN	I-NP
O	1248	1255	laminin	laminin	NN	I-NP
O	1256	1264	receptor	receptor	NN	I-NP
O	1265	1266	(	(	(	O
O	1266	1270	67LR	67LR	NN	B-NP
O	1270	1271	)	)	)	O
O	1272	1274	as	as	IN	B-PP
O	1275	1276	a	a	DT	B-NP
B-Cellular_component	1277	1281	cell	cell	NN	I-NP
I-Cellular_component	1282	1289	surface	surface	NN	I-NP
O	1290	1298	receptor	receptor	NN	I-NP
O	1299	1302	for	for	IN	B-PP
O	1303	1307	EGCG	EGCG	NN	B-NP
O	1308	1312	that	that	WDT	B-NP
O	1313	1321	mediates	mediate	VBZ	B-VP
O	1322	1325	the	the	DT	B-NP
O	1326	1336	anticancer	anticancer	JJ	I-NP
O	1337	1345	activity	activity	NN	I-NP
O	1346	1348	of	of	IN	B-PP
O	1349	1353	EGCG	EGCG	NN	B-NP
O	1354	1355	[	[	(	O
O	1355	1357	16	16	CD	B-NP
O	1357	1358	]	]	)	O
O	1358	1359	.	.	.	O

O	1360	1364	67LR	67LR	NN	B-NP
O	1365	1368	has	have	VBZ	B-VP
O	1369	1373	been	be	VBN	I-VP
O	1374	1379	shown	show	VBN	I-VP
O	1380	1382	to	to	TO	I-VP
O	1383	1385	be	be	VB	I-VP
O	1386	1399	overexpressed	overexpresse	VBN	I-VP
O	1400	1402	on	on	IN	B-PP
O	1403	1406	the	the	DT	B-NP
B-Cellular_component	1407	1411	cell	cell	NN	I-NP
I-Cellular_component	1412	1419	surface	surface	NN	I-NP
O	1420	1422	of	of	IN	B-PP
O	1423	1430	various	various	JJ	B-NP
B-Cell	1431	1436	tumor	tumor	NN	I-NP
I-Cell	1437	1442	cells	cell	NNS	I-NP
O	1443	1444	[	[	(	O
O	1444	1446	17	17	CD	B-NP
O	1446	1447	]	]	)	O
O	1447	1448	.	.	.	O

O	1449	1451	It	It	PRP	B-NP
O	1452	1455	was	be	VBD	B-VP
O	1456	1466	postulated	postulate	VBN	I-VP
O	1467	1471	that	that	IN	B-SBAR
O	1472	1476	67LR	67LR	NN	B-NP
O	1477	1482	plays	play	VBZ	B-VP
O	1483	1484	a	a	DT	B-NP
O	1485	1496	significant	significant	JJ	I-NP
O	1497	1501	role	role	NN	I-NP
O	1502	1504	in	in	IN	B-PP
O	1505	1508	the	the	DT	B-NP
B-Cancer	1509	1514	tumor	tumor	NN	I-NP
O	1515	1526	progression	progression	NN	I-NP
O	1527	1530	and	and	CC	O
O	1531	1541	speculated	speculate	VBD	B-VP
O	1542	1546	that	that	IN	B-SBAR
O	1547	1554	studies	study	NNS	B-NP
O	1555	1564	conducted	conduct	VBN	B-VP
O	1565	1567	to	to	TO	B-VP
O	1568	1574	define	define	VB	I-VP
O	1575	1578	the	the	DT	B-NP
O	1579	1587	function	function	NN	I-NP
O	1588	1590	of	of	IN	B-PP
O	1591	1595	67LR	67LR	NN	B-NP
O	1596	1601	could	could	MD	B-VP
O	1602	1609	provide	provide	VB	I-VP
O	1610	1611	a	a	DT	B-NP
O	1612	1615	new	new	JJ	I-NP
O	1616	1624	approach	approach	NN	I-NP
O	1625	1627	to	to	TO	B-PP
B-Cancer	1628	1634	cancer	cancer	NN	B-NP
O	1635	1645	prevention	prevention	NN	I-NP
O	1645	1646	.	.	.	O

O	1647	1653	Indeed	Indeed	RB	B-ADVP
O	1653	1654	,	,	,	O
O	1655	1665	expression	expression	NN	B-NP
O	1666	1668	of	of	IN	B-PP
O	1669	1671	67	67	CD	B-NP
O	1672	1674	LR	LR	NN	I-NP
O	1675	1682	confers	confer	VBZ	B-VP
O	1683	1687	EGCG	EGCG	NN	B-NP
O	1688	1702	responsiveness	responsiveness	NN	I-NP
O	1703	1705	to	to	TO	B-PP
B-Cell	1706	1711	tumor	tumor	NN	B-NP
I-Cell	1712	1717	cells	cell	NNS	I-NP
O	1718	1720	in	in	FW	B-ADVP
O	1721	1725	vivo	vivo	FW	I-ADVP
O	1726	1727	[	[	(	O
O	1727	1729	18	18	CD	B-NP
O	1729	1730	]	]	)	O
O	1730	1731	.	.	.	O

O	1732	1739	Vitamin	Vitamin	NN	B-NP
O	1740	1741	A	A	NN	I-NP
O	1741	1742	,	,	,	O
O	1743	1747	also	also	RB	B-VP
O	1748	1753	known	know	VBN	I-VP
O	1754	1756	as	as	IN	B-PP
O	1757	1764	retinol	retinol	NN	B-NP
O	1764	1765	,	,	,	O
O	1766	1778	participates	participate	VBZ	B-VP
O	1779	1781	in	in	IN	B-PP
O	1782	1795	physiological	physiological	JJ	B-NP
O	1796	1806	activities	activity	NNS	I-NP
O	1807	1814	related	relate	VBN	B-VP
O	1815	1817	to	to	TO	B-PP
O	1818	1821	the	the	DT	B-NP
B-Anatomical_system	1822	1828	immune	immune	JJ	I-NP
I-Anatomical_system	1829	1835	system	system	NN	I-NP
O	1835	1836	,	,	,	O
O	1837	1848	maintenance	maintenance	NN	B-NP
O	1849	1851	of	of	IN	B-PP
B-Tissue	1852	1862	epithelial	epithelial	JJ	B-NP
O	1863	1866	and	and	CC	I-NP
B-Tissue	1867	1873	mucosa	mucosa	JJ	I-NP
I-Tissue	1874	1881	tissues	tissue	NNS	I-NP
O	1881	1882	,	,	,	O
O	1883	1889	growth	growth	NN	B-NP
O	1889	1890	,	,	,	O
O	1891	1903	reproduction	reproduction	NN	B-NP
O	1903	1904	,	,	,	O
O	1905	1908	and	and	CC	O
B-Organ	1909	1913	bone	bone	NN	B-NP
O	1914	1925	development	development	NN	I-NP
O	1925	1926	.	.	.	O

O	1927	1929	It	It	PRP	B-NP
O	1930	1935	comes	come	VBZ	B-VP
O	1936	1940	from	from	IN	B-PP
O	1941	1947	animal	animal	NN	B-NP
O	1948	1955	sources	source	NNS	I-NP
O	1955	1956	,	,	,	O
O	1957	1961	such	such	JJ	B-PP
O	1962	1964	as	as	IN	I-PP
B-Developing_anatomical_structure	1965	1969	eggs	egg	NNS	B-NP
O	1969	1970	,	,	,	O
B-Organism_subdivision	1971	1975	meat	meat	NN	B-NP
O	1975	1976	,	,	,	O
B-Organism_substance	1977	1981	milk	milk	NN	B-NP
O	1981	1982	,	,	,	O
O	1983	1989	cheese	cheese	NN	B-NP
O	1989	1990	,	,	,	O
O	1991	1996	cream	cream	NN	B-NP
O	1996	1997	,	,	,	O
B-Organ	1998	2003	liver	liver	NN	B-NP
O	2003	2004	,	,	,	O
B-Organ	2005	2011	kidney	kidney	NN	B-NP
O	2011	2012	,	,	,	O
O	2013	2016	cod	cod	NN	B-NP
O	2017	2020	and	and	CC	O
O	2021	2028	halibut	halibut	NN	B-NP
O	2029	2033	fish	fish	NN	I-NP
B-Organism_substance	2034	2037	oil	oil	NN	I-NP
O	2037	2038	.	.	.	O

O	2039	2041	In	In	FW	B-ADVP
O	2042	2047	vitro	vitro	FW	I-ADVP
O	2048	2051	and	and	CC	O
O	2052	2054	in	in	IN	B-PP
O	2055	2061	animal	animal	NN	B-NP
O	2062	2068	models	model	NNS	I-NP
O	2068	2069	,	,	,	O
O	2070	2072	it	it	PRP	B-NP
O	2073	2076	has	have	VBZ	B-VP
O	2077	2081	been	be	VBN	I-VP
O	2082	2094	demonstrated	demonstrate	VBN	I-VP
O	2095	2099	that	that	IN	B-SBAR
O	2100	2107	vitamin	vitamin	NN	B-NP
O	2108	2109	A	A	NN	I-NP
O	2110	2112	is	be	VBZ	B-VP
O	2113	2121	involved	involve	VBN	I-VP
O	2122	2124	in	in	IN	B-PP
O	2125	2128	the	the	DT	B-NP
O	2129	2139	regulation	regulation	NN	I-NP
O	2140	2143	and	and	CC	I-NP
O	2144	2153	promotion	promotion	NN	I-NP
O	2154	2156	of	of	IN	B-PP
O	2157	2163	growth	growth	NN	B-NP
O	2164	2167	and	and	CC	O
O	2168	2183	differentiation	differentiation	NN	B-NP
O	2184	2186	of	of	IN	B-PP
O	2187	2191	many	many	JJ	B-NP
B-Cell	2192	2197	cells	cell	NNS	I-NP
O	2198	2199	[	[	(	O
O	2199	2201	19	19	CD	B-NP
O	2201	2202	]	]	)	O
O	2202	2203	.	.	.	O

O	2204	2207	The	The	DT	B-NP
O	2208	2214	visual	visual	JJ	I-NP
O	2215	2223	function	function	NN	I-NP
O	2224	2226	of	of	IN	B-PP
O	2227	2234	vitamin	vitamin	NN	B-NP
O	2235	2236	A	A	NN	I-NP
O	2237	2244	depends	depend	VBZ	B-VP
O	2245	2247	on	on	IN	B-PP
O	2248	2251	its	its	PRP$	B-NP
O	2252	2259	natural	natural	JJ	I-NP
O	2260	2263	and	and	CC	I-NP
O	2264	2273	synthetic	synthetic	JJ	I-NP
O	2274	2285	derivatives	derivative	NNS	I-NP
O	2285	2286	,	,	,	O
O	2287	2296	retinoids	retinoid	NNS	B-NP
O	2297	2298	[	[	(	O
O	2298	2300	20	20	CD	B-NP
O	2300	2301	]	]	)	O
O	2301	2302	.	.	.	O

O	2303	2306	All	All	DT	B-NP
O	2306	2307	-	-	HYPH	I-NP
O	2307	2312	trans	trans	AFX	I-NP
O	2312	2313	-	-	HYPH	I-NP
O	2313	2321	retinoic	retinoic	JJ	I-NP
O	2322	2326	acid	acid	NN	I-NP
O	2327	2328	(	(	(	O
O	2328	2332	ATRA	ATRA	NN	B-NP
O	2332	2333	)	)	)	O
O	2333	2334	,	,	,	O
O	2335	2338	the	the	DT	B-NP
O	2339	2345	active	active	JJ	I-NP
O	2346	2356	derivative	derivative	NN	I-NP
O	2357	2359	of	of	IN	B-PP
O	2360	2367	vitamin	vitamin	NN	B-NP
O	2368	2369	A	A	NN	I-NP
O	2369	2370	,	,	,	O
O	2371	2374	has	have	VBZ	B-VP
O	2375	2379	been	be	VBN	I-VP
O	2380	2384	well	well	RB	I-VP
O	2385	2395	documented	document	VBN	I-VP
O	2396	2398	as	as	IN	B-PP
O	2399	2400	a	a	DT	B-NP
O	2401	2407	growth	growth	NN	I-NP
O	2408	2411	and	and	CC	O
O	2412	2427	differentiation	differentiation	NN	B-NP
O	2428	2434	factor	factor	NN	I-NP
O	2435	2437	in	in	IN	B-PP
O	2438	2442	many	many	JJ	B-NP
B-Tissue	2443	2450	tissues	tissue	NNS	I-NP
O	2451	2454	and	and	CC	I-NP
B-Cell	2455	2460	cells	cell	NNS	I-NP
O	2460	2461	,	,	,	O
O	2462	2465	and	and	CC	O
O	2466	2472	proved	prove	VBD	B-VP
O	2473	2475	to	to	TO	I-VP
O	2476	2478	be	be	VB	I-VP
O	2479	2481	an	an	DT	B-NP
O	2482	2491	effective	effective	JJ	I-NP
O	2492	2501	treatment	treatment	NN	I-NP
O	2502	2504	to	to	TO	B-PP
O	2505	2509	many	many	JJ	B-NP
O	2510	2518	diseases	disease	NNS	I-NP
O	2519	2528	including	include	VBG	B-PP
B-Cancer	2529	2536	cancers	cancer	NNS	B-NP
O	2537	2538	[	[	(	O
O	2538	2540	21	21	CD	B-NP
O	2540	2541	]	]	)	O
O	2541	2542	,	,	,	O
O	2543	2544	[	[	(	O
O	2544	2546	22	22	CD	B-NP
O	2546	2547	]	]	)	O
O	2547	2548	.	.	.	O

O	2549	2558	Retinoids	Retinoid	NNS	B-NP
O	2559	2564	exert	exert	VBP	B-VP
O	2565	2570	their	their	PRP$	B-NP
O	2571	2584	physiological	physiological	JJ	I-NP
O	2585	2595	activities	activity	NNS	I-NP
O	2596	2603	through	through	IN	B-PP
O	2604	2612	retinoid	retinoid	NN	B-NP
O	2613	2621	receptor	receptor	NN	I-NP
B-Cellular_component	2622	2629	nuclear	nuclear	JJ	I-NP
O	2630	2638	proteins	protein	NNS	I-NP
O	2639	2643	that	that	WDT	B-NP
O	2644	2650	belong	belong	VBP	B-VP
O	2651	2653	to	to	TO	B-PP
O	2654	2657	the	the	DT	B-NP
O	2658	2669	superfamily	superfamily	NN	I-NP
O	2670	2672	of	of	IN	B-PP
O	2673	2680	steroid	steroid	NN	B-NP
O	2680	2681	/	/	SYM	B-NP
O	2681	2688	thyroid	thyroid	NN	I-NP
O	2689	2696	hormone	hormone	NN	I-NP
O	2697	2706	receptors	receptor	NNS	I-NP
O	2706	2707	,	,	,	O
O	2708	2710	of	of	IN	B-PP
O	2711	2716	which	which	WDT	B-NP
O	2717	2722	there	there	EX	B-NP
O	2723	2726	are	be	VBP	B-VP
O	2727	2730	two	two	CD	B-NP
O	2731	2738	classes	class	NNS	I-NP
O	2738	2739	,	,	,	O
O	2740	2748	retinoic	retinoic	JJ	B-NP
O	2749	2753	acid	acid	NN	I-NP
O	2754	2763	receptors	receptor	NNS	I-NP
O	2764	2765	(	(	(	O
O	2765	2769	RARs	RAR	NNS	B-NP
O	2769	2770	)	)	)	O
O	2771	2774	and	and	CC	O
O	2775	2778	the	the	DT	B-NP
O	2779	2787	retinoic	retinoic	JJ	I-NP
O	2787	2788	-	-	HYPH	I-NP
O	2788	2789	X	X	NN	I-NP
O	2790	2799	receptors	receptor	NNS	I-NP
O	2800	2801	(	(	(	O
O	2801	2805	RXRs	RXR	NNS	B-NP
O	2805	2806	)	)	)	O
O	2806	2807	,	,	,	O
O	2808	2812	each	each	DT	B-NP
O	2813	2815	of	of	IN	B-PP
O	2816	2821	which	which	WDT	B-NP
O	2822	2825	has	have	VBZ	B-VP
O	2826	2831	three	three	CD	B-NP
O	2832	2840	subtypes	subtype	NNS	I-NP
O	2840	2841	,	,	,	O
O	2842	2847	alpha	alpha	NN	B-NP
O	2847	2848	,	,	,	O
O	2849	2853	beta	beta	NN	B-NP
O	2853	2854	,	,	,	O
O	2855	2858	and	and	CC	O
O	2859	2864	gamma	gamma	NN	B-NP
O	2865	2866	[	[	(	O
O	2866	2868	23	23	CD	B-NP
O	2868	2869	]	]	)	O
O	2869	2870	,	,	,	O
O	2871	2872	[	[	(	O
O	2872	2874	24	24	CD	B-NP
O	2874	2875	]	]	)	O
O	2875	2876	.	.	.	O

O	2877	2880	The	The	DT	B-NP
O	2881	2888	natural	natural	JJ	I-NP
O	2889	2896	ligands	ligand	NNS	I-NP
O	2897	2900	for	for	IN	B-PP
O	2901	2904	the	the	DT	B-NP
O	2905	2909	RARs	RAR	NNS	I-NP
O	2910	2913	are	be	VBP	B-VP
O	2914	2918	ATRA	ATRA	NN	B-NP
O	2919	2922	and	and	CC	O
O	2923	2926	its	its	PRP$	B-NP
O	2927	2940	stereoisomers	stereoisomer	NNS	I-NP
O	2941	2942	9	9	CD	I-NP
O	2942	2943	-	-	HYPH	I-NP
O	2943	2946	cis	cis	NN	I-NP
O	2946	2947	-	-	HYPH	I-NP
O	2947	2949	RA	RA	NN	I-NP
O	2950	2953	and	and	CC	I-NP
O	2954	2956	13	13	CD	I-NP
O	2956	2957	-	-	HYPH	I-NP
O	2957	2960	cis	cis	NN	I-NP
O	2960	2961	-	-	HYPH	O
O	2961	2963	RA	RA	NN	B-NP
O	2963	2964	,	,	,	O
O	2965	2972	whereas	whereas	IN	O
O	2973	2977	RXRs	RXR	NNS	B-NP
O	2978	2981	are	be	VBP	B-VP
O	2982	2991	activated	activate	VBN	I-VP
O	2992	2994	by	by	IN	B-PP
O	2995	2996	9	9	CD	B-NP
O	2996	2997	-	-	HYPH	I-NP
O	2997	3000	cis	cis	NN	I-NP
O	3000	3001	-	-	HYPH	I-NP
O	3001	3003	RA	RA	NN	I-NP
O	3004	3008	only	only	RB	B-ADVP
O	3008	3009	.	.	.	O

O	3010	3014	ATRA	ATRA	NN	B-NP
O	3015	3019	acts	act	VBZ	B-VP
O	3020	3027	through	through	IN	B-PP
O	3028	3031	RAR	RAR	NN	B-NP
O	3032	3034	to	to	TO	B-VP
O	3035	3052	transcriptionally	transcriptionally	RB	I-VP
O	3053	3061	activate	activate	VB	I-VP
O	3062	3068	target	target	NN	B-NP
O	3069	3074	genes	gene	NNS	I-NP
O	3074	3075	,	,	,	O
O	3076	3080	such	such	JJ	B-PP
O	3081	3083	as	as	IN	I-PP
O	3084	3094	cytochrome	cytochrome	NN	B-NP
O	3095	3099	P450	P450	NN	I-NP
O	3100	3103	and	and	CC	O
O	3104	3109	CRABI	CRABI	NN	B-NP
O	3110	3111	[	[	(	O
O	3111	3113	24	24	CD	B-NP
O	3113	3114	]	]	)	O
O	3114	3115	.	.	.	O

O	3116	3120	This	This	DT	B-NP
O	3121	3126	study	study	NN	I-NP
O	3127	3130	was	be	VBD	B-VP
O	3131	3139	designed	design	VBN	I-VP
O	3140	3142	to	to	TO	B-VP
O	3143	3151	identify	identify	VB	I-VP
O	3152	3153	a	a	DT	B-NP
O	3154	3158	food	food	NN	I-NP
O	3159	3168	component	component	NN	I-NP
O	3169	3173	that	that	WDT	B-NP
O	3174	3179	could	could	MD	B-VP
O	3180	3182	be	be	VB	I-VP
O	3183	3194	effectively	effectively	RB	I-VP
O	3195	3199	used	use	VBN	I-VP
O	3200	3202	in	in	IN	B-PP
O	3203	3214	combination	combination	NN	B-NP
O	3215	3219	with	with	IN	B-PP
O	3220	3224	EGCG	EGCG	NN	B-NP
O	3225	3228	and	and	CC	O
O	3229	3231	to	to	TO	B-VP
O	3232	3243	investigate	investigate	VB	I-VP
O	3244	3247	the	the	DT	B-NP
O	3248	3257	mechanism	mechanism	NN	I-NP
O	3258	3260	of	of	IN	B-PP
O	3261	3267	action	action	NN	B-NP
O	3268	3270	of	of	IN	B-PP
O	3271	3275	this	this	DT	B-NP
O	3276	3287	combination	combination	NN	I-NP
O	3287	3288	.	.	.	O

O	3289	3291	By	By	IN	B-PP
O	3292	3297	using	use	VBG	B-VP
O	3298	3300	in	in	FW	B-ADVP
O	3301	3306	vitro	vitro	FW	I-ADVP
O	3307	3310	and	and	CC	O
O	3311	3313	in	in	FW	B-NP
O	3314	3318	vivo	vivo	FW	I-NP
O	3319	3326	systems	system	NNS	I-NP
O	3327	3336	involving	involve	VBG	B-VP
O	3337	3338	a	a	DT	B-NP
O	3339	3345	highly	highly	RB	I-NP
O	3346	3356	metastatic	metastatic	JJ	I-NP
O	3357	3362	mouse	mouse	NN	I-NP
B-Cell	3363	3366	B16	B16	NN	I-NP
I-Cell	3367	3375	melanoma	melanoma	NN	I-NP
I-Cell	3376	3380	cell	cell	NN	I-NP
I-Cell	3381	3385	line	line	NN	I-NP
O	3386	3387	[	[	(	O
O	3387	3389	25	25	CD	B-NP
O	3389	3390	]	]	)	O
O	3390	3391	,	,	,	O
O	3392	3394	we	we	PRP	B-NP
O	3395	3400	found	find	VBD	B-VP
O	3401	3405	that	that	IN	B-SBAR
O	3406	3410	ATRA	ATRA	NN	B-NP
O	3411	3419	enhances	enhance	VBZ	B-VP
O	3420	3423	the	the	DT	B-NP
B-Cancer	3424	3433	antitumor	antitumor	JJ	I-NP
O	3434	3442	activity	activity	NN	I-NP
O	3443	3445	of	of	IN	B-PP
O	3446	3450	EGCG	EGCG	NN	B-NP
O	3451	3453	by	by	IN	B-PP
O	3454	3466	upregulating	upregulate	VBG	B-VP
O	3467	3470	the	the	DT	B-NP
O	3471	3473	67	67	CD	I-NP
O	3474	3476	LR	LR	NN	I-NP
O	3477	3487	expression	expression	NN	I-NP
O	3488	3495	through	through	IN	B-PP
O	3496	3499	RAR	RAR	NN	B-NP
O	3499	3500	.	.	.	O

